Boston Scientific Co. (NYSE:BSX - Get Free Report) EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total value of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares of the company's stock, valued at $3,316,788.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Wendy Carruthers also recently made the following trade(s):
- On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $75.33, for a total value of $526,029.39.
Boston Scientific Stock Up 0.2 %
BSX stock opened at $76.55 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $77.99. The company has a 50-day moving average of $75.01 and a two-hundred day moving average of $67.81. The stock has a market capitalization of $112.30 billion, a price-to-earnings ratio of 64.33, a price-to-earnings-growth ratio of 2.65 and a beta of 0.78.
New Government Policy to Wipe Out Seniors Wealth
From Oasis Gold | Ad
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.
Click Here To Get Your FREE Guide Now!
Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion during the quarter, compared to analysts' expectations of $3.68 billion. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.32 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in BSX. Louisiana State Employees Retirement System acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $5,116,000. Glenmede Trust Co. NA lifted its position in Boston Scientific by 12.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider's stock valued at $551,000 after acquiring an additional 1,123 shares in the last quarter. Sierra Summit Advisors LLC bought a new stake in Boston Scientific in the 4th quarter valued at $8,038,000. TD Asset Management Inc lifted its position in Boston Scientific by 10.7% in the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider's stock valued at $93,417,000 after acquiring an additional 155,565 shares in the last quarter. Finally, HealthInvest Partners AB acquired a new stake in Boston Scientific in the 4th quarter valued at $3,746,000. Institutional investors and hedge funds own 89.07% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on BSX. Citigroup boosted their price objective on Boston Scientific from $85.00 to $87.00 and gave the stock a "buy" rating in a research report on Wednesday, May 22nd. JPMorgan Chase & Co. increased their price objective on Boston Scientific from $72.00 to $82.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Robert W. Baird increased their price objective on Boston Scientific from $79.00 to $84.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Boston Scientific from $63.00 to $73.00 and gave the company a "hold" rating in a research note on Thursday, April 25th. Finally, Needham & Company LLC reissued a "buy" rating and set a $82.00 target price on shares of Boston Scientific in a research note on Tuesday, June 18th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $77.41.
View Our Latest Stock Analysis on Boston Scientific
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
